AstraZeneca/Merck's Lynparza gets approval in Japan for early breast cancer subtype
XtockImages/iStock via Getty Images         

The Japanese Ministry of Health, Labour, and Welfare approvedÂ AstraZeneca (NASDAQ:AZN) and Merck's (NYSE:MRK) Lynparza as adjuvant therapy for patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence.
The approval was backed by data from a phase 3 trial called OlympiA.
"With this approval, Lynparza becomes the first and only PARP inhibitor available for patients with BRCA-mutated HER2-negative early breast cancer in Japan," saidÂ Eliav Barr, senior vice president, head of Global Clinical Development and chief medical officer, MSD Research Laboratories.